Maryland Center for Multiple Sclerosis: Clinical Trials Open for Enrollment
Opportunities are available for individuals with Multiple Sclerosis to participate in several new clinical trials at the University of Maryland Center for Multiple Sclerosis. These studies are either currently enrolling or will be enrolling shortly. The studies vary in design, duration, criteria for eligibility, number of MRI scans, and other details. The following is a very brief summary of each study. You may obtain further information by calling Kerry Naunton, R.N., 410-328-1885 or Schrese Tucker, R.N., 410-328-7602 at the MS Center.
- The Novartis trial is a study of an oral medication named fingolimod. Fingolimod is a once daily medication that acts on certain types of white blood cells called lymphocytes. It makes their cells move away from sites of inflammation and redirects them towards lymph nodes and other places in the body where they rest. The study is 24 months long and has 3 treatment groups: high dose fingolimod, low dose fingolimod and Copaxone. It is a blinded study which means that neither your study doctor nor you will know which dosing group you are in.
Investigator: Robert Shin, MD
Eligibility: This trial is designed for people 18-65 years of age who have relapsing remitting multiple sclerosis and who have had at least 1 relapse in the past year. Subjects who are interested must not be on any of the injectable medicines routinely prescribed for the treatment of MS during the trial.
Currently recruiting clinical trial opportunities are constantly changing. Please keep in touch if you are interested in trials!
For more information about the Maryland Center for Multiple Sclerosis, please call 410-328-5605.
This page was last updated: April 9, 2014